Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001066386 | SCV001231393 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001570850 | SCV001795212 | uncertain significance | not provided | 2022-11-21 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Revvity Omics, |
RCV001570850 | SCV003833047 | uncertain significance | not provided | 2019-07-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003160546 | SCV003856291 | uncertain significance | Cardiovascular phenotype | 2023-03-08 | criteria provided, single submitter | clinical testing | The p.E1104K variant (also known as c.3310G>A), located in coding exon 21 of the FLNC gene, results from a G to A substitution at nucleotide position 3310. The glutamic acid at codon 1104 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |